Overview

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell

Status:
Recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

The objective of the study is the evaluation of efficacy and safety of obinutuzumab preemptive treatment at the time of the molecular relapse after first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma patients.

Phase:

Phase 2

Details

Lead Sponsor:

Polish Lymphoma Research Group

Collaborator:

Roche Pharma AG

Treatments:

Obinutuzumab